database > company
XDx Inc.
Biotech Specialty Pharma  Advamed Member
3260 Bayshore Blvd.
Brisbane, CA 94005 USA
phone:415-287-2300
fax:415-287-2456
Symbol Private
Founded 2000
Employees
          www.xdx.com
Research Sector Biotech Specialty Pharma
Summary Description
Molecular diagnostics to translate immune status into clinically actionable information.
Management
Pierre Cassigneul, President and Chief Executive Officer; Jay M. Moyes, Chief Financial Officer; im Yee, Chief Medical Officer;Tod Klingler, Vice President Information Sciences; Dirk Lammerts, Vice President Corporate Development; Mitchell J. Nelles, Vice President R&D/Technical Operations
Keywords
molecular diagnostics, immune, heart transplant, non-invasive, rejection, advamed

Comment | Printable Version | Modify profile Jan. 15, 2009

Description
XDx develops molecular diagnostics that translate an individual's immune status into clinically actionable information.
Products / Services
AlloMap molecular expression testing is a non-invasive method for determining the risk of rejection in heart transplant recipients. The test translates the complex signals of the immune system's multiple genes and pathways, specifically those associated with heart transplant rejection, into an objective, actionable score.


2010-03-10-1863